Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From ALK-Abello A/S
Average R&D spending by the top 25 biopharma companies increased as a percent of sales from 14.4% in 2010 to 17% in 2020, according to an EY report.
Seven international translational research bodies recommend five actions to help better prepare for future outbreaks. Plus an overview of recent COVID-19-focused collaborations.
Evolving challenges will keep the COVID-19 pipeline active, while oncology, immunology and CNS are areas also expected to see much progress in 2022. Industry executives look forward to the year in therapeutic R&D.
Totals for aggregate deals and in the M&A, alliance and divestment categories were similar among the 10 busiest deal makers from 2020 to 2021, but COVID-19 may have driven a more hectic deal-making pace overall in 2020.
- In Vitro Diagnostics
- Drug Delivery
- Other Names / Subsidiaries
- Allergy Laboratories, Inc.
- Crystal Laboratory LLC